Clinical trial

A Study to Determine Progression-free Survival (PFS) and Evaluate Participant Experience for Participants With Metastatic Anaplastic Lymphoma Kinase-positive (ALK+) Non-Small Cell Lung Cancer (NSCLC) Treated With Anaplastic Lymphoma Kinase (ALK) Inhibitors

NCT03546894

StatusCOMPLETED

Study typeOBSERVATIONAL

Start date2018-07-23

PhaseN/A

Study timeline

Study start (actual)2018-07-23Date precision: day

Registry last updated2024-07-15

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Anaplastic Lymphoma Kinase-positiveunresolved

Carcinoma Non-small-cell Lungunresolved

Interventions

BrigatinibDRUG · verified · RxNorm: brigatinib

AlectinibDRUG · verified · RxNorm: alectinib

CeritinibDRUG · verified · RxNorm: ceritinib

LorlatinibDRUG · verified · RxNorm: lorlatinib

Any FDA Approved ALK InhibitorsDRUG

Sponsors & collaborators

Takedalead sponsor

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT03546894 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.